SELLAS Life Sciences Group, Inc. Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31)
SELLAS Life Sciences Group, Inc. (SLS) had Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) of 90.10% as of 2017-12-29, per its 10-Q filed 2018-08-14.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssumptionsExpectedVolatilityRate · last filed 2018-08-14
| Period end | Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) | Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) 0 month | Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) 0 month as first filed | Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-29 | 90.10% 10-Q · filed 2018-08-14 | |||
| 2016-12-31 | 77.13% 10-Q · filed 2017-11-09 | |||
| 2016-07-29 | 106.63% 10-Q · filed 2017-11-09 | |||
| 2016-06-29 | 106.63% 10-Q · filed 2016-11-09 | |||
| 2013-05-08 | 75.34% 10-Q · filed 2017-11-09 | 110.77% 10-Q · filed 2016-11-09 | 75.34% 10-Q · filed 2013-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |